Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...

The study revealed that patients receiving a 15mg/kg dose of nipocalimab every two weeks experienced a notable reduction in ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Positive Results from Six-Month Phase 2 Trial of Mavorixafor in ...

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Immutep (IMMP) has released an update. Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...